{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:13:25Z","timestamp":1776248005654,"version":"3.50.1"},"reference-count":101,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Topical retinoids are the cornerstone of the treatment of multiple dermatological conditions. Long established in acne therapy, they exert effects on keratinization, inflammation, fibroblast activity, and collagen remodeling, suggesting a potential role in both the prevention and treatment of acne scars. This narrative review summarizes current evidence on the use of topical retinoids in acne vulgaris and acne scarring, focusing on different retinoid molecules, formulation technologies, and combination strategies. A review of published clinical and experimental studies evaluating tretinoin, adapalene, tazarotene, and trifarotene was performed, including their use as monotherapy and in combination with other topical agents or procedural interventions. The available data indicate that topical retinoids have a well-established position in acne treatment, can improve the appearance of atrophic acne scars, reduce the progression of scarring, and support skin remodeling. Advances in formulation technologies have improved tolerability, while combination approaches with agents such as benzoyl peroxide, antibiotics or procedural techniques have shown additive or synergistic effects, particularly in more severe cases. Nevertheless, much of the evidence regarding novel formulations is derived from small or heterogeneous study populations. In conclusion, topical retinoids represent a relevant therapeutic option in acne vulgaris and acne scarring, from monotherapy in mild cases to components of multimodal treatment protocols in more severe disease. Further large-scale, comparative studies are needed to better define the optimal clinical use of advanced drug delivery systems for topical retinoids.<\/jats:p>","DOI":"10.3390\/ph19040620","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:15:59Z","timestamp":1776244559000},"page":"620","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Topical Retinoids in Acne Vulgaris and Acne Scars\u2014From Monotherapy to Combining Regimens"],"prefix":"10.3390","volume":"19","author":[{"given":"Aleksandra","family":"Tobiasz","sequence":"first","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4944-5388","authenticated-orcid":false,"given":"Alina","family":"Jankowska-Konsur","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1717-4280","authenticated-orcid":false,"given":"Danuta","family":"Nowicka","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-021-00594-8","article-title":"50 Years of Topical Retinoids for Acne: Evolution of Treatment","volume":"22","author":"Baldwin","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00005-019-00562-5","article-title":"Retinoids as an Immunity-modulator in Dermatology Disorders","volume":"67","author":"Chen","year":"2019","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/ada.2019.87443","article-title":"Retinoids: Active molecules influencing skin structure formation in cosmetic and dermatological treatments","volume":"36","author":"Zasada","year":"2019","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris","volume":"90","author":"Reynolds","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ski, \u0141., Skopek, R., Palusi\u0144ska, M., Schenk, T., Stengel, S., Lewicki, S., Kraj, L., Kami\u0144ski, P., and Zelent, A. (2020). Retinoic Acid and Its Derivatives in Skin. Cells, 9.","DOI":"10.3390\/cells9122660"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/12034754211035091","article-title":"A Clinician\u2019s Guide to Topical Retinoids","volume":"26","author":"Motamedi","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_7","unstructured":"(2026, February 02). PubChem [Internet] Bethesda (MD) National Library of Medicine (US) National Center for Biotechnology Information. PubChem Compound Summary for CID 444795: Retinoic Acid, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Retinoic-Acid."},{"key":"ref_8","unstructured":"(2026, February 02). PubChem [Internet] Bethesda (MD) National Library of Medicine (US) National Center for Biotechnology Information. PubChem Compound Summary for CID 60164, Adapalene, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Adapalene."},{"key":"ref_9","unstructured":"(2026, February 02). PubChem [Internet] Bethesda (MD) National Library of Medicine (US) National Center for Biotechnology Information. PubChem Compound Summary for CID 5381, Tazarotene, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Tazarotene."},{"key":"ref_10","unstructured":"(2026, February 02). PubChem [Internet] Bethesda (MD) National Library of Medicine (US) National Center for Biotechnology Information. PubChem Compound Summary for CID 11518241, Trifarotene, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Trifarotene."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/ciia.2006.1.4.327","article-title":"Retinoids in the treatment of skin aging: An overview of clinical efficacy and safety","volume":"1","author":"Mukherjee","year":"2006","journal-title":"Clin. Interv. Aging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40257-016-0185-5","article-title":"Topical Retinoids: Therapeutic Mechanisms in the Treatment of Photodamaged Skin","volume":"17","author":"Riahi","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s13555-025-01344-y","article-title":"Recommendations to Improve Outcomes in Acne and Acne Sequelae: A Focus on Trifarotene and Other Retinoids","volume":"15","author":"Issa","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/ijd.17546","article-title":"One Acne\u2122: A holistic management approach to improve overall skin quality and treatment outcomes in acne with or without sensitive skin","volume":"64","author":"Kircik","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s13346-024-01681-z","article-title":"Application of quality by design in optimization of nanoformulations: Principle, perspectives and practices","volume":"15","author":"Birla","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e14247","DOI":"10.1016\/j.heliyon.2023.e14247","article-title":"An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques","volume":"9","author":"Pingale","year":"2023","journal-title":"Heliyon"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.36849\/JDD.7146","article-title":"Tretinoin Review With Newer Formulations: Providing Effective and Tolerable Solutions in Clinical Practice","volume":"22","author":"Baldwin","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_18","first-page":"638","article-title":"40 years of topical tretinoin use in review","volume":"12","author":"Baldwin","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","article-title":"Why Topical Retinoids Are Mainstay of Therapy for Acne","volume":"7","author":"Leyden","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40257-024-00893-w","article-title":"Comparing Tretinoin to Other Topical Therapies in the Treatment of Skin Photoaging: A Systematic Review","volume":"25","author":"Siddiqui","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-3083.2010.03798.x","article-title":"A pilot methodology study for the photographic assessment of post-inflammatory hyperpigmentation in patients treated with tretinoin","volume":"25","author":"Rossi","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13287-022-02908-x","article-title":"Retinoic acid inhibits the angiogenesis of human embryonic stem cell-derived endothelial cells by activating FBP1-mediated gluconeogenesis","volume":"13","author":"Yang","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: A journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2023.09.004","article-title":"Topical tretinoin alters skin microbiota in patients with mild acne","volume":"14","author":"Martinez","year":"2024","journal-title":"JAAD Int."},{"key":"ref_25","first-page":"s148","article-title":"Polymeric Emulsion Technology Applied to Tretinoin","volume":"18","author":"Kircik","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-020-00559-3","article-title":"The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris","volume":"21","author":"Tyring","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_27","first-page":"1218","article-title":"Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability","volume":"18","author":"Pariser","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2050313X20929798","DOI":"10.1177\/2050313X20929798","article-title":"Treatment of post-menopausal acne with tretinoin lotion 0.05% delivers rapid results and concomitant benefits","volume":"8","author":"Sangha","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_29","first-page":"1147","article-title":"Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate or Severe Acne Vulgaris in Adult Females","volume":"18","author":"Harper","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2026, February 02). ALTRENO (Tretinoin) Lotion (2018). US Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209353s000lbl.pdf."},{"key":"ref_31","first-page":"E53","article-title":"A Split-face, Controlled Study to Assess the Compatibility of Tretinoin 0.05% Acne Lotion with Facial Foundation Makeup","volume":"13","author":"Bhatia","year":"2020","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4103\/ijd.IJD_781_20","article-title":"Predictors of Quality of Life in Adults and Adolescents with Acne: A Cross-Sectional Study","volume":"67","author":"Yildirim","year":"2022","journal-title":"Indian. J. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/jdv.15419","article-title":"Acne relapses: Impact on quality of life and productivity","volume":"33","author":"Dreno","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00403-021-02256-5","article-title":"Efficacy assessments of tretinoin-loaded nano lipid carriers in acne vulgaris: A double blind, split-face randomized clinical study","volume":"314","author":"Samadi","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pharma.2021.05.004","article-title":"Emulgel for improved topical delivery of Tretinoin: Formulation design and characterization","volume":"80","author":"Malavi","year":"2022","journal-title":"Ann. Pharm. Fr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e32275","DOI":"10.1016\/j.heliyon.2024.e32275","article-title":"Individual sol-gel microencapsulation of benzoyl peroxide and tretinoin enables controlled release onto the skin","volume":"10","author":"Hakak","year":"2024","journal-title":"Heliyon"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13555-023-01095-8","article-title":"Real-World Adverse Events Associated with Encapsulated Benzoyl Peroxide\/Tretinoin, 3%\/0.1%, and Encapsulated Benzoyl Peroxide, 5","volume":"14","author":"Poteate","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/09546634.2020.1720579","article-title":"Efficacy and safety comparison of combination of 0.04% tretinoin microspheres plus 1% clindamycin versus their monotherapy in patients with acne vulgaris: A phase 3, randomized, double-blind study","volume":"32","author":"Dogra","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.36849\/JDD.5641","article-title":"Tolerability and Efficacy of Clindamycin\/Tretinoin versus Adapalene\/Benzoyl Peroxide in the Treatment of Acne Vulgaris","volume":"20","author":"Aschoff","year":"2021","journal-title":"J. Drugs Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e14724","DOI":"10.1111\/dth.14724","article-title":"Efficacy and tolerability of short contact therapy with tretinoin, clindamycin, and glycolic acid gel in acne: A randomized, controlled, assessor-blinded two-center trial: The MASCOTTE study","volume":"34","author":"Bertolani","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.35248\/2155-9554.19.10.503","article-title":"Efficacy and Tolerability of a Tretinoin 0.02%, Clindamycin 0.8% and Glycolic Acid 4% Gel in Acne: A Multicenter, Prospective, Pragmatic, Assessor-Blinded, 12-Week Trial on 159 Subjects","volume":"10","author":"Milani","year":"2019","journal-title":"J. Clin. Exp. Dermatol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14764172.2017.1349323","article-title":"Fractional carbon dioxide (CO2) laser combined with topical tretinoin for the treatment of different forms of cystic acne","volume":"19","year":"2017","journal-title":"J. Cosmet. Laser Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev-pharmtox-052120-104428","article-title":"Synthetic Retinoids Beyond Cancer Therapy","volume":"62","author":"Gudas","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clindermatol.2004.03.013","article-title":"Comparison of topical retinoids in the treatment of acne","volume":"22","author":"Rigopoulos","year":"2004","journal-title":"Clin. Dermatol."},{"key":"ref_45","first-page":"238","article-title":"Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%","volume":"75","author":"Dosik","year":"2005","journal-title":"Cutis"},{"key":"ref_46","first-page":"455","article-title":"Cumulative irritancy potential of adapalene cream 0.1% compared with adapalene gel 0.1% and several tretinoin formulations","volume":"72","author":"Brand","year":"2003","journal-title":"Cutis"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Matharoo, N.S., Garimella, H.T., Truong, T.M., Badeti, S., Cui, J.X., Talluri, S.R., Virani, A., Rao, B.K., and Michniak-Kohn, B. (2025). A Mechanistic Physiologically Based Pharmacokinetic\/Pharmacodynamic Modeling Approach Informed by In Vitro and Clinical Studies for Topical Administration of Adapalene Gels. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091108"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e14777","DOI":"10.1111\/dth.14777","article-title":"Preparation and evaluation of adapalene nanostructured lipid carriers for targeted drug delivery in acne","volume":"34","author":"Koohestani","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1208\/s12249-021-01989-w","article-title":"Development and Evaluation of Topical Delivery of Microemulsions Containing Adapalene (MEs-Ap) for Acne","volume":"22","author":"Shao","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41598-024-51392-1","article-title":"Resolving acne with optimized adapalene microspongeal gel, in vivo and clinical evaluations","volume":"14","author":"Yehia","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10283","DOI":"10.2147\/IJN.S480639","article-title":"Functional Evaluation of Niosomes Utilizing Surfactants in Nanomedicine Applications","volume":"19","author":"Gao","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/10837450.2023.2233613","article-title":"Exploring the use of niosomes in cosmetics for efficient dermal drug delivery","volume":"28","author":"Alkarawi","year":"2023","journal-title":"Pharm. Dev. Technol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8874333","DOI":"10.1155\/bmri\/8874333","article-title":"A Novel Cationic Niosome Formulation for Topical Delivery of Adapalene","volume":"2025","author":"Haddadi","year":"2025","journal-title":"Biomed. Res. Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1346-8138.2005.tb00739.x","article-title":"Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris","volume":"32","author":"Korkut","year":"2005","journal-title":"J. Dermatol."},{"key":"ref_56","first-page":"582","article-title":"Adapalene\/Benzoyl Peroxide Gel 0.3%\/2.5%: Effective Acne Therapy Regardless of Age or Gender","volume":"16","author":"Werschler","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jdv.13194","article-title":"Safety and efficacy of adapalene 0.1%\/benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication\u2014Results from the non-interventional cohort study ELANG","volume":"29","author":"Gollnick","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","first-page":"23","article-title":"Adapalene-benzoyl Peroxide Gel is Efficacious and Safe in Adult Female Acne, with a Profile Comparable to that Seen in Teen-aged Females","volume":"9","author":"Gold","year":"2016","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_59","first-page":"264","article-title":"Efficacy and Safety of Adapalene 0.3%\/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects With Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin","volume":"17","author":"Johnson","year":"2018","journal-title":"J. Drugs Dermatol."},{"key":"ref_60","first-page":"5","article-title":"A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne","volume":"30","author":"Michael","year":"2025","journal-title":"Skin. Ther. Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.36849\/JDD.9213","article-title":"Assessing Cutibacterium Acnes Susceptibility With Clindamycin Phosphate 1.2%\/Adapalene 0.15%\/Benzoyl Peroxide 3.1% Gel Use: Six-Month Analysis","volume":"24","author":"Ghannoum","year":"2025","journal-title":"J. Drugs Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2166346","DOI":"10.1080\/09546634.2023.2166346","article-title":"Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies","volume":"34","author":"Draelos","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"602","DOI":"10.36849\/JDD.2020.4959","article-title":"New Polymeric Once-Daily Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Pooled Phase 3 Pediatric Analysis","volume":"19","author":"Eichenfield","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/tjd.tjd_128_21","article-title":"The comparative study to determine the efficacy of 0.05% tazarotene gel versus 0.1% adapalene gel in patients of facial acne vulgaris","volume":"16","author":"Deshmukh","year":"2022","journal-title":"Turk. J. Dermatol."},{"key":"ref_65","first-page":"100185","article-title":"Tackling acne vulgaris by fabrication of tazarotene-loaded essential oil-based microemulsion: In vitro and in vivo evaluation","volume":"5","author":"Badawi","year":"2023","journal-title":"Int. J. Pharm. X"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"114346","DOI":"10.1016\/j.ejpb.2024.114346","article-title":"Formulation development of tazarotene-loaded PLGA nanoparticles for follicular delivery in the treatment of inflammatory skin diseases","volume":"200","author":"Kshirsagar","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_67","first-page":"256","article-title":"Tazarotene versus tazarotene plus clindamycin\/benzoyl peroxide in the treatment of acne vulgaris: A multicenter, double-blind, randomized parallel-group trial","volume":"5","author":"Tanghetti","year":"2006","journal-title":"J. Drugs Dermatol."},{"key":"ref_68","first-page":"99","article-title":"Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne","volume":"91","author":"Dhawan","year":"2013","journal-title":"Cutis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D30N81Z2H4","article-title":"Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris","volume":"13","author":"Tanghetti","year":"2007","journal-title":"Dermatol. Online J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s40261-017-0568-2","article-title":"Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial","volume":"37","author":"Maiti","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_71","first-page":"442","article-title":"Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene","volume":"179","author":"Aubert","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s40265-019-01218-6","article-title":"Trifarotene: First Approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.bmcl.2018.04.036","article-title":"Structure-based design of Trifarotene (CD5789), a potent and selective RARgamma agonist for the treatment of acne","volume":"28","author":"Thoreau","year":"2018","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","article-title":"Randomized phase 3 evaluation of trifarotene 50 mug\/g cream treatment of moderate facial and truncal acne","volume":"80","author":"Tan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jdv.15794","article-title":"Long-term safety and efficacy of trifarotene 50 mug\/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne","volume":"34","author":"Fowler","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","first-page":"275","article-title":"Facilitating facial retinization through barrier improvement","volume":"78","author":"Draelos","year":"2006","journal-title":"Cutis"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Dreno, B., Chavda, R., Julia, V., Khammari, A., Blanchet-Rethore, S., and Krishnaswamy, J.K. (2021). Transcriptomics Analysis Indicates Trifarotene Reverses Acne-Related Gene Expression Changes. Front. Med., 8.","DOI":"10.3389\/fmed.2021.745822"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s13555-022-00788-w","article-title":"Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: A Case Series","volume":"12","author":"Lain","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_79","first-page":"1","article-title":"A Multimodal Approach to Acne-Induced Post-Inflammatory Hyperpigmentation: Trifarotene as a Long-Term Intervention","volume":"29","author":"Conte","year":"2024","journal-title":"Skin. Ther. Lett."},{"key":"ref_80","first-page":"1","article-title":"An Overview on the Management of Atrophic Acne Scars: The Role of Trifarotene as an Adjunct","volume":"29","author":"Conte","year":"2024","journal-title":"Skin. Ther. Lett."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.36849\/JDD.7630","article-title":"Sequential Treatment With Topical Trifarotene and Injectable NASHA Gel in Acne Scars: A Case Series","volume":"22","author":"Belmontesi","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_82","first-page":"s109","article-title":"The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: What does recent research show and what does it mean to the clinician?","volume":"12","author":"Kircik","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaad.2022.04.021","article-title":"Acne scarring-pathophysiology, diagnosis, prevention and education: Part I","volume":"90","author":"Jennings","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wang, K., Yang, Z., Ma, Y., Liu, W., Li, G., Xu, X., and Li, Q. (2025). Retinoids in scarless skin regeneration: From molecular mechanisms to therapeutic strategies. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1683851"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00128071-200102030-00002","article-title":"Optimal management of acne to prevent scarring and psychological sequelae","volume":"2","author":"Layton","year":"2001","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1524-4725.1988.tb03483.x","article-title":"Retinoic acid in the treatment of keloids","volume":"14","year":"1988","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2133.1991.tb06048.x","article-title":"Topical retinoic acid in the treatment of fine acne scarring","volume":"125","author":"Harris","year":"1991","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/jocd.15584","article-title":"Topical management of acne scars: The uncharted terrain","volume":"22","author":"Bikash","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Dumitriu Buzia, O., P\u0103duraru, A.M., Stefan, C.S., Dinu, M., Coco\u0219, D.I., Nwabudike, L.C., and Tatu, A.L. (2023). Strategies for Improving Transdermal Administration: New Approaches to Controlled Drug Release. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041183"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-4362.1995.tb04381.x","article-title":"New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin","volume":"34","author":"Schmidt","year":"1995","journal-title":"Int. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1365-4362.1999.00586.x","article-title":"Tretinoin-iontophoresis in atrophic acne scars","volume":"38","author":"Schmidt","year":"1999","journal-title":"Int. J. Dermatol."},{"key":"ref_92","first-page":"84","article-title":"Flattening of atrophic acne scars by using tretinoin by iontophoresis","volume":"12","author":"Knor","year":"2004","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0974-2077.129964","article-title":"Combination therapy in the management of atrophic acne scars","volume":"7","author":"Garg","year":"2014","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13555-018-0231-8","article-title":"Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars","volume":"8","author":"Loss","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/1346-8138.16942","article-title":"Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%\/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24\u2009weeks and assessment of atrophic acne scars using three-dimensional image analysis","volume":"50","author":"Tanizaki","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jamafacial.2018.1404","article-title":"Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial","volume":"21","author":"Afra","year":"2019","journal-title":"JAMA Facial Plast. Surg."},{"key":"ref_97","first-page":"S14","article-title":"Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports","volume":"17","author":"Miranti","year":"2024","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s13555-023-01042-7","article-title":"Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study","volume":"13","author":"Schleicher","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Dereiah, S., Ghori, M.U., and Conway, B.R. (2024). A Systematic Review of Spironolactone Nano-Formulations for Topical Treatment of Skin Hyperandrogenic Disorders and Chronic Wounds. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010027"},{"key":"ref_100","first-page":"3","article-title":"Newer approaches in topical combination therapy for acne","volume":"16","author":"Fu","year":"2011","journal-title":"Skin. Ther. Lett."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/CCID.S574341","article-title":"Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review","volume":"18","author":"Tommasino","year":"2025","journal-title":"Clin. Cosmet. Investig. Dermatol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/620\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:22:14Z","timestamp":1776244934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":101,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ph19040620"],"URL":"https:\/\/doi.org\/10.3390\/ph19040620","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}